Boston Trust Walden Corp Lowers Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Boston Trust Walden Corp trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 129,655 shares of the company’s stock after selling 28,296 shares during the quarter. Boston Trust Walden Corp owned approximately 0.42% of Medpace worth $43,279,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Westwind Capital increased its holdings in shares of Medpace by 800.1% in the 2nd quarter. Westwind Capital now owns 380,929 shares of the company’s stock valued at $156,886,000 after acquiring an additional 338,610 shares during the period. Findlay Park Partners LLP purchased a new position in Medpace in the first quarter valued at about $90,247,000. Clearbridge Investments LLC raised its holdings in Medpace by 302.4% in the first quarter. Clearbridge Investments LLC now owns 260,411 shares of the company’s stock worth $105,245,000 after purchasing an additional 195,698 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Medpace by 38.3% during the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock valued at $182,692,000 after buying an additional 122,800 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Medpace by 62.3% during the second quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock valued at $127,941,000 after buying an additional 119,257 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on MEDP shares. Guggenheim reduced their price objective on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft reduced their price target on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research report on Wednesday, July 24th. UBS Group cut Medpace from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and reduced their target price for the company from $415.00 to $345.00 in a research report on Wednesday, September 25th. Finally, Robert W. Baird cut Medpace from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $413.00 to $349.00 in a research note on Wednesday. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $380.00.

Medpace Stock Up 0.7 %

Medpace stock opened at $330.22 on Friday. Medpace Holdings, Inc. has a 52 week low of $239.00 and a 52 week high of $459.77. The stock has a 50-day moving average price of $351.45 and a 200 day moving average price of $381.28. The company has a market capitalization of $10.24 billion, a price-to-earnings ratio of 28.92, a price-to-earnings-growth ratio of 1.74 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.22 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 11.77 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.